ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Search Videos by Topic or Participant
Browse by Series:

Best Practices in NSCLC Molecular Testing, Part II

Panelists: David R. Gandara, MD, UC Davis; Corey J. Langer, MD, Penn Medicine; Alan B. Sandler, MD, OHSU; Mark A. Socinski, MD, University of Pitt
Published: Friday, Jan 25, 2013
For High-Definition, Click
David Gandara, MD, begins the conversation by asking a question about the timing of treatment in relation to diagnosis.

Alan B. Sandler, MD, states that while deciding on a treatment early on is important, he also sticks to the idea to refrain from ordering a test until he plans on doing something with the information. Depending on the likelihood of positive results, Sandler can adjust the plan.

In some cases, Corey J. Langer, MD, says, such as in node positive patients who have undergone definitive resection and have plans for resection, exceptions can be made. Certain tests can take multiple weeks to deliver results.

Gandara concludes the conversation by mentioning a new program led by Alliance and the National Cancer Institute where 8,000 early stage patients will undergo molecular testing for trials and their information will be available for later use.

View Part I of the discussion
Slider Left
Slider Right
For High-Definition, Click
David Gandara, MD, begins the conversation by asking a question about the timing of treatment in relation to diagnosis.

Alan B. Sandler, MD, states that while deciding on a treatment early on is important, he also sticks to the idea to refrain from ordering a test until he plans on doing something with the information. Depending on the likelihood of positive results, Sandler can adjust the plan.

In some cases, Corey J. Langer, MD, says, such as in node positive patients who have undergone definitive resection and have plans for resection, exceptions can be made. Certain tests can take multiple weeks to deliver results.

Gandara concludes the conversation by mentioning a new program led by Alliance and the National Cancer Institute where 8,000 early stage patients will undergo molecular testing for trials and their information will be available for later use.

View Part I of the discussion
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x